ArticleJournal of neuro-oncology2011
The detection of CMV pp65 and IE1 in glioblastoma multiforme.
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.
- Viral infection and glioma: a meta-analysis of prognosis.BMC cancer · 2020Pooled it
- Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.The Journal of clinical investigation · 2020Trial
- Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Immunotherapy and targeted therapy for high grade gliomas: current and future directions.Journal of neuro-oncology · 2025Review
- Immunologic specificity in glioblastoma: Antigen discovery and translational implications.Neuro-oncology advances · 2025Review
- Mutant IDH impairs chromatin binding by PDGFB to promote chromosome instability.bioRxiv : the preprint server for biology · 2025Article
- Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.Vaccines · 2024Review
- Article
- Tumor Antigens beyond the Human Exome.International journal of molecular sciences · 2024Review
- Viruses in glioblastoma: an update on evidence and clinical trials.BJC reports · 2024Review
- Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease.International journal of molecular sciences · 2024Review
- Higher Human Cytomegalovirus (HCMV) Specific IgG Antibody Levels in Plasma Samples from Patients with Metastatic Brain Tumors Are Associated with Longer Survival.Medicina (Kaunas, Lithuania) · 2023Article
- Review
- EphA2 is a functional entry receptor for HCMV infection of glioblastoma cells.PLoS pathogens · 2023Article
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments.Brain tumor research and treatment · 2022Review
- Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.Journal of hematology & oncology · 2022Review
- Novel Pharmacological Treatment Options in Pediatric Glioblastoma-A Systematic Review.Cancers · 2022Review
- Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovirus (CMV) with GBM, and we sought to confirm these findings in a large series of patients with primary GBM from our institution. Immunohistochemical analysis of paraffin embedded tissue sections was performed on 49 newly diagnosed GBM tumors, the largest series reported to date. We confirmed the presence of CMV pp65 on 25/49 (51%) and of IE1 on 8/49 (16%) of these tumors. While pp65 and IE1 are generally found in the nucleus of cells that are permissibly infected by CMV, GBM in this series had mostly cytoplasmic staining, with only 16% having nuclear staining for one or both of these antigens. We infected GBM cell lines with a laboratory strain of CMV, and found that most of the staining was cytoplasmic, with some perinuclear localization of IE1. To test the potential for CMV infected GBM cells to be recognized by CMV pp65 and IE1 specific cytotoxic T lymphocytes (CTL), we used CMV infected GBM cell lines in cytotoxicity assays with human leukocyte antigen partially matched CMV CTL. Lysis of CMV infected GBM tumor cells was accentuated by pre-treating these cell lines with either the demethylating agent decitabine or interferon-γ, both of which were shown to increase MHC Class I and II expression on tumor cells in vitro. These studies confirm the presence of CMV pp65 or IE1 on approximately half of GBM, with the possibility that CMV positive tumor cells can be recognized by CMV pp65/IE1 specific T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.